Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial…
13 Mar 2026
WHO directs antibiotic development to priority pathogens
The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a move to direct research towards developing urgently needed antibiotics. The three Target…
13 Mar 2026
PRISM BioLab partners with Receptor.AI for molecule discovery
PRISM BioLab has formed a collaboration with Receptor.AI to integrate AI and physics-guided technologies in the discovery of orally available small molecules. The partnership targets membrane proteins, intracellular protein–protein interactions…
13 Mar 2026
PsiQuantum and National Cancer Center Japan partner on quantum computing
PsiQuantum and the National Cancer Center Japan have entered a collaborative research agreement to drive advancements in utility-scale quantum computing within drug discovery and oncology. The partnership aims to investigate…
12 Mar 2026
Vima banks $100m in Series A to progress Parkinson’s drug
Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill, VIM0423. This takes the company’s total funding round raise to…
12 Mar 2026
Eli Lilly finds impurity in compounded tirzepatide
Eli Lilly has warned of high levels of an impurity in certain compounded versions of its blockbuster glucagon-like peptide-1 receptor agonist (GLP-1RA) tirzepatide. Lilly issued the public warning after conducting…
12 Mar 2026
Bavarian Nordic and SII sign agreement for chikungunya vaccine production
Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP). The contract covers a…